Aquestive Therapeutics (AQST) Debt Ratio (2017 - 2026)

Aquestive Therapeutics' Debt Ratio history runs 10 years deep, the most recent figure standing at 0.42 for Q1 2026.

• On a quarterly basis, Debt Ratio rose 25.83% year-over-year to 0.42 in Q1 2026; TTM through Mar 2026 was 0.42, a 25.83% increase from a year earlier, with the FY2025 full-year figure at 0.23, down 27.08% from the prior year.
• Debt Ratio grew to 0.42 in Q1 2026 per AQST's latest filing, from 0.23 in the prior quarter.
• Across five years, Debt Ratio topped out at 1.02 in Q3 2022 and bottomed at 0.15 in Q2 2024.
• The 5-year median for Debt Ratio is 0.42 (2026), against an average of 0.56.
• Across the five-year window, Debt Ratio sank 85.21% in 2024 and soared 151.16% in 2025, its largest moves.
• Year by year, Debt Ratio stood at 0.91 in 2022, then plunged by 47.53% to 0.48 in 2023, then tumbled by 33.11% to 0.32 in 2024, then dropped by 27.08% to 0.23 in 2025, then jumped by 77.76% to 0.42 in 2026.
• Per Business Quant, the three latest AQST Debt Ratio figures stand at 0.42 (Q1 2026), 0.23 (Q4 2025), and 0.22 (Q3 2025).